HK Stock Market Move | CSTONE PHARMA-B (02616) rose more than 5%, Pralutinib has been included in the national medical insurance list, the company's 2.0 pipeline matrix continues to expand.

CSTONE PHARMA-B(02616) rose more than 5%, as of the time of writing, it is up by 5.57% to HK$6.07, with a trading volume of HK$22.7042 million. On the news front, CStone Pharmaceuticals recently announced that its RET inhibitor, Pralsetinib (Pralsetinib capsules, 100 mg), has been successfully included in the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List released by the National Medical Security Administration of China. This list will officially take effect on January 1, 2026. As of now, CStone Pharmaceuticals has successfully promoted 4 innovative drugs for market approval, with 3 of them having completed clinical trials and obtained marketing approval in China, all of which have been included in the national medical insurance list. A research report released by Tianfeng in August this year pointed out that it is expected that the inclusion of Pralsetinib in medical insurance will accelerate volume growth. CStone Pharmaceuticals' pre-clinical pipeline includes more than nine potential candidate drugs such as specific antibodies, ADCs, focusing on FIC/BIC research, covering multiple therapeutic areas such as oncology, autoimmunity, and inflammatory diseases. The company's innovative in-house ADC technology platform, featuring optimized proprietary linkers, improves the release of tumor-selective effective payloads. The platform supports multiple ADC products in pipeline 2.0, providing continuous momentum for the company's future development.